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Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. 
An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in 
ECM protein metabolites may provide insight to tissue changes. Dietary fish oils (n-3 PUFA) might affect the inflammation 
driven tissue turnover. The aim was to evaluate ECM metabolites in patients with PsA compared to healthy individuals and 
investigate the effects of n-3 PUFA. The 24-week randomized, double-blind, placebo-controlled trial of PUFA included 142 
patients with PsA. Fifty-seven healthy individuals were included for comparison. This study is a sub-study investigating 
biomarkers of tissue remodelling as secondary outcomes. Serum samples at baseline and 24 weeks and healthy individuals 
were obtained, while a panel of ECM metabolites reflecting bone and soft tissue turnover were measured by ELISAs: PRO-
C1, PRO-C3, PRO-C4, C1M, C3M, C4M, CTX-I and Osteocalcin (OC). C1M, PRO-C3, PRO-C4 and C4M was found to 
be elevated in PsA patients compared to the healthy individuals (from 56 to 792%, all p < 0.0001), where no differences 
were found for OC, CTX-I, PRO-C1 and C3M. PRO-C3 was increased by 7% in patients receiving n-3 PUFA after 24 weeks 
compared to baseline levels (p = 0.002). None of the other biomarkers was changed with n-3 PUFA treatment. This indicates 
that tissue turnover is increased in PsA patients compared to healthy individuals, while n-3 PUFA treatment for 24 weeks did 
not have an effect on tissue turnover. Trial registration NCT01818804. Registered 27 March 2013–Completed 18 February 
2016. https:// clini caltr ials. gov/ ct2/ show/ NCT01 818804? term= NCT01 81880 4& rank=1
Keywords Psoriatic arthritis · Collagens · Biomarkers · Fish oil
Rheumatology
INTERNATIONAL 
 * Signe Holm Nielsen 
 shn@nordicbio.com
 Samra Sardar 
 samrasardar@gmail.com
 Anne Sofie Siebuhr 
 aso@nordicbio.com
 Annette Schlemmer 
 ANESHL@rm.dk
 Erik Berg Schmidt 
 ebs@rn.dk
 Anne-Christine Bay-Jensen 
 acbj@nordicbio.com
 Morten A. Karsdal 
 mk@nordicbio.com
 Jeppe Hagstrup Christensen 
 jeppe.hagstrup.christensen@rn.dk
 Salome Kristensen 
 sakr@rn.dk
1 Immunoscience, Nordic Bioscience, Herlev Hovedgade 207, 
2730 Herlev, Denmark
2 Department of Biotechnology and Biomedicine, Technical 
University of Denmark, Lyngby, Denmark
3 Department of Rheumatology, Aalborg University Hospital, 
Aalborg, Denmark
4 Department of Cardiology, Aalborg University Hospital, 
Aalborg, Denmark
5 Department of Clinical Medicine, Aalborg University, 
Aalborg, Denmark
6 Department of Nephrology, Aalborg University Hospital, 
Aalborg, Denmark
7 Department of Clinical Medicine, Aalborg University, 
Aalborg, Denmark
1066 Rheumatology International (2021) 41:1065–1077
1 3
Abbreviations
PsA  Psoreatic arthritis
ECM  Extracellular matrix
PUFA  Polyunsaturated fatty acids
PRO-C1  Collagen type I formation
PRO-C3  Collagen type III formation
PRO-C4  Collagen type IV formation
C1M  MMP-mediated collagen type I degradation
C3M  MMP-mediated collagen type III degradation
C4M  MMP-mediated collagen type IV degradation
MMP  Matrix metalloproteinase
OC  Osteocalcin
CTX-I  C-terminal telopeptide of collagen type I
RA  Rheumatoid arthritis
CASPAR  Classification criteria for psoriatic arthritis
TJC  Tender joint count
VAS  Visual analogue scale
HAQ  Health assessment questionnaire
ASDAS  Ankylosing spondylitis disease activity score
BASDAI  Bath ankylosing spondylitis disease activity 
index
BASMI  Bath ankylosing spondylitis metrology index
LEI  Leeds enthesitis index
SPARCC  Spondyloarthritis research consortium of 
Canada enthesitis index
PASI  Psoriasis area and severity index
SD  Standard deviation
Background
Psoriatic Arthritis (PsA) is a chronic, inflammatory arthrop-
athy of the peripheral and axial skeleton. PsA, in general, 
remains poorly defined because of its heterogeneous clinical 
presentation [1]. Pathologically, it is an autoimmune dis-
ease characterized by inflammation of the joints, entheseal 
sites and skin [2]. A major cause of disability in PsA is the 
destruction of the extracellular matrix (ECM) of cartilage, 
bone, and soft tissues of the joint [3, 4]. This is attributed to 
effects of pro-inflammatory cellular infiltrate and elaboration 
of inflammatory cytokines underlying the pathology of PsA. 
The inflammatory joint milieu induces increased expression 
of proteolytic enzymes, such as the matrix metalloprotein-
ases (MMPs), That mediate enhanced turnover of the ECM 
[5, 6]. These ECM fragments may enter circulation and may 
be utilised as serological biomarkers of ECM turnover.
Degradation and formation of ECM proteins are in a tight 
equilibrium ensuring tissue health and homeostasis. This 
equilibrium is perturbed by the inflammatory load in PsA 
patients leading to altered balance of the ECM [7]. Dur-
ing this process, excessive levels of collagen fragments 
(neo-epitopes) are released into the circulation and may 
act as important biomarkers in the study of tissue-related 
remodelling. These biomarkers can also provide insight 
into identification of key molecular pathways leading to 
enhanced connective tissue remodelling.
The ECM can be divided into the basement membrane 
and interstitial matrix. Collagen types I and III are the most 
abundant collagens in soft tissue and are located in the 
interstitial matrix. Collagen type I is therefore predominant 
in both bone matrix and tissue. Collagen type III is found 
extensively in connective tissues, such as skin, and vascular 
system, and is found to be a key player in wound healing 
together with collagen type I [8, 9]. Collagen type IV is 
the main collagen component of the basement membrane, 
underlying epithelial or endothelial cells functioning as bar-
rier between tissue compartments [10]. Besides soft tissues, 
the bone remodelling processes underlying PsA pathology 
can also be assessed objectively by the use of serological 
biomarkers. Here, the C-terminal telopeptide of collagen 
type I (CTX-I) measures the degradation of collagen type 
I by cathepsin K, an enzyme secreted by osteoclasts dur-
ing bone resorption [11]. Several studies have established 
CTX-I as a specific and sensitive biomarker of bone resorp-
tion [12]. A second marker of bone turnover is osteocalcin 
(OC), which is one of the major non-collagenous proteins 
of bone matrix synthesized by active osteoblasts [13]. OC 
is a well-established markers of bone formation, and are 
found to correlate with histomorphometric bone formation 
indices [13, 14]. Increased bone remodelling and elevated 
levels of both degradation and formation markers have been 
documented in PsA patients previously [15]. An example of 
this was presented in 2015, where biomarkers of collagen 
type I degradation (C1M) and collagen type III degradation 
(C3M) were increased in PsA patients compared to healthy 
individuals.
The outlook of PsA has significantly changed in the past 
decades due to availability of various treatment options 
including conventional and biological disease-modifying 
antirheumatic drugs (DMARDs) and the recently released 
targeted synthetic disease-modifying antirheumatic drugs 
[16]. However, while other types of arthritis have seen sig-
nificant improvements in outcomes with newer treatments, 
approximately half of the PsA patients still experience an 
insufficient response [17, 18].
Marine n-3 polyunsaturated fatty acids (PUFAs), such 
as eicosapentaenoic acid (EPA; 20:5n-3) and docosahexae-
noic acid (DHA; 22:6n-3), found in fish and fish oils, have 
been proposed as potential therapeutic or supplementary 
agents in a variety of acute and chronic inflammatory set-
tings. At sufficiently high intakes, n-3 PUFAs can act as 
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anti-inflammatory agents by decreasing the production 
of arachidonic acid–derived inflammatory eicosanoids 
like prostaglandins and leukotrienes, pro-inflammatory 
cytokines, reactive oxygen species and the expression of 
adhesion molecules [19, 20]. Evidence of their clinical ben-
efit is reasonably strong in some settings (eg, in RA [21, 22], 
cardiovascular disease [23], neurological diseases [24–26] 
and osteoarthritis [27, 28]) and weak in others (e.g., inflam-
matory bowel diseases and asthma). Recent randomized and 
controlled trial using n-3 PUFA has demonstrated a reduc-
tion in joint pain and non-steroidal anti-inflammatory drugs 
NSAIDs use in patients with PsA and RA [20, 29]. The clini-
cal efficacy of n-3 PUFAs in arthritis can be attributed to 
their effect on inflammation and/or bone remodelling. Both 
mechanisms have been addressed individually in in vivo and 
in vitro setups [30–34]. However, the relative contribution 
of these mechanisms in various types of arthritis remains 
unexplored.
Biomarkers of ECM turnover can provide this valuable 
information regarding mechanism of action of n-3 PUFAs 
in arthritis. In this study, we aimed to explore the hypothesis 
that ECM turnover described by neo-epitope biomarkers can 
separate PsA patients from healthy individuals and patients 
treated with n-3 PUFA from the placebo group.
Methods
Study design and population
A randomized, double-blind, placebo-controlled trial was 
conducted and the subjects, study design, inclusion and 
exclusion criteria, randomization and sample size calculation 
has been described in details previously [29]. For 24 weeks, 
patients were assigned to a daily intake of either 3 g of 
marine n-3 PUFA (50% EPA and 50% DHA) or 3 g of olive 
oil (approximately 80% of oleic acid and 20% linoleic acid). 
Treatment with biological DMARDs or oral corticosteroids 
was exclusion criterion. Conventional DMARDs, NSAID 
and paracetamol intake were allowed.
All participants gave their written informed consent 
and the regional ethics committee of Northern Den-
mark approved the study (reference number N20120076). 
The study was conducted in accordance with the Dec-
laration of Helsinki and registered at ClinicalTrials.gov 
(NCT01818804). Good Clinical Practice (GCP) inspectors 
monitored the study, and the GCP ethical and scientific qual-
ity requirements were fulfilled. The primary outcome of the 
study was disease activity measured by tender and swollen 
joint count [29]. This study is a sub-study investigating bio-
markers of tissue remodelling as secondary outcomes. Blood 
samples were obtained from the study participants, at base-
line and at the study end, in non-fasting state. Serum sam-
ples were collected and processed immediately after collect-
ing according to standard operating procedures and stored at 
− 80 °C until analysis. For this sub-study, fifty-seven healthy 
individuals were included as controls, randomly selected and 
purchased from Lee Biosolutions (CA, US). Serum samples 
from the healthy individuals were collected in 2018 and pro-
cessed immediately after collecting according to standard 
operating procedures and stored at − 80 °C until analysis.
Biomarker analysis
ECM remodelling was assessed by a panel of biomarkers 
including validated ELISAs of Matrix-metalloproteinase-
generated neo-epitope fragments of collagen type I, III and 
IV was chosen to assess collagen degradation (C1M, C3M, 
and C4M, respectively) and formation (PRO-C1, PRO-C3 
and PRO-4, respectively) were run by manufactures instruc-
tion. Bone remodelling was assessed by osteocalcin (OC) 
and CTX-I. OC was measured using the  Elecsys® osteocal-
cin kit (Roche Diagnostic Ltd., Switzerland), while CTX-I 
was measured by the  Elecsys® β-CrossLaps assay (Roche 
diagnostics Ltd., Switzerland). Reference levels for OC 
and CTX-I were obtained from the package insert of the 
Table 1  Overview of measured 





 PRO-C1 Formation of collagen type I [43]
 PRO-C3 Formation of collagen type III [44]
 PRO-C4 Formation of collagen type IV [45]
 C1M MMP-2, -9, -13 mediated degradation of collagen type I [46]
 C3M MMP-9 mediated degradation of collagen type III [47]
 C4M MMP-2, -9, -12 mediated degradation of collagen type IV [48]
Bone turnover
 OC Osteocalcin [41]
 CTX-I C-terminal telopeptide of collagen type I [42]
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individual assays (n = 6). The biomarkers are described in 
Table 1.
Statistical analysis
Sample size calculation has been described previously [29]. 
Analyses were performed in MedCalc (version 14.8.1) and 
GraphPad Prism (version 8). A p value below 0.05 was 
considered statistically significant. Baseline characteris-
tics of healthy individuals, placebo and n-3 PUFA-treated 
patients were presented as mean ± standard deviation (SD) 
for continuous variables and number (frequency) for cat-
egorical variables. Differences between the groups were 
calculated using Pearson’s Chi-square for categorical vari-
ables and ANOVA (parametric) or Kruskal–Wallis test 
(non-parametric) for continuous variables. An unpaired t test 
was used to calculate statistical differences between PsA 
patients and healthy individuals, when data passed the Bar-
tlett’s variation test. If data did not pass, a non-parametric 
Wilcoxon–Mann–Whitney t test was used. A paired t test 
was used for evaluation of treatment at baseline and after 
24 weeks. Spearman’s correlations were used to analyse the 
associations between the biomarker and clinical feature at 
baseline and after 24 weeks.
Results
Demographics
A total of 142 patients with PsA, 71 patients in the n-3 
PUFA group and 71 patients in the placebo group (Fig. 1) 
and 57 healthy individuals were included in this study. 
Patient demographics and clinical characterization for the 
intervention group were compared to baseline characteris-
tics, disease activity scores, and biomarker levels (Table 2) 
without significant difference and the excluded patients did 
not differ from those who completed the trial.
Associations between the biomarkers and clinical 
parameters
Associations between clinical parameters and biomarkers are 
found in Table 3. A negative correlation was found between 
CTX-I and DAS-28-CRP (r = − 0.199, p = 0.018), PRO-
C3 and TJC (r = − 0.267, p = 0.01) and OC; CTX-I; PRO-
C1 and SJC (r = − 0.234, p = 0.005; r = − 247, p = 0.003; 
r = − 0.236, p = 0.005, respectively). A positive correlation 
was found for C3M and SPARCC (r = 0.171, p = 0.042). No 
correlation was found for the other clinical measures and 
ASDAS-CRP, PASI, LEI, HAQ, BASDAI and VAS pain.
Extracellular matrix turnover
The biomarkers measuring ECM turnover in soft tissue, 
PRO-C1, measuring collagen type I formation, did not 
show a difference between the healthy controls and PsA 
patients (p = 0.056, Fig. 2a), while C1M, measuring colla-
gen type I degradation was 56% elevated in patients with 
PsA (p < 0.0001, Fig. 2b). A 76% increase was found for 
PRO-C3, collagen type III formation in patients with PsA 
compared to healthy individuals (p < 0.0001, Fig. 2c), while 
no difference was found for the collagen type III degradation 
marker C3M (p = 0.462, Fig. 2d). An increase in both forma-
tion and degradation of collagen type IV, reflected by PRO-
C4 and C4M, was found (both p < 0.0001 and an increase of 
792% and 70%, respectively, Fig. 2e and Fig. 2f).
The ECM biomarkers measuring bone formation, OC, 
and bone degradation, CTX-I, were not statistically different 
in PsA patients compared to healthy individuals (Fig. 3). A 
trend towards a decreased level of OC in PsA patients was 
observed (p = 0.06, Fig. 2a
).
Effect of n‑3 PUFA supplementation on bone 
and tissue turnover biomarkers
Neither of the bone turnover biomarkers, OC or CTX-I, 
showed changes in either patients treated with placebo or 
patients treated with n-3 PUFA for 24 weeks (Fig. 4a and 
Fig. 4b). PRO-C3 was the only tissue biomarker which was 
significantly elevated by 7% in patients receiving PUFA-3 
(p = 0.002, Fig. 4d), none of the other tissue biomarkers 
showed a significant difference with n-3 PUFA treatment 
from placebo.
Discussion
Tissue remodelling is a feature of PsA pathology. Treatment 
of PsA therefore aims not only to resolve inflammation but 
also to halt or slow down the ongoing tissue damage. In the 
present study, we measured ECM turnover biomarkers in 
healthy individuals, biologic naïve patients with PsA and 
biologic naïve patients with PsA treated with n-3 PUFA for 
24 weeks. To our knowledge, this is the first study assessing 
tissue neo-epitope biomarkers in a randomised clinical study 
of patients with PsA. The evaluated tissue biomarkers are 
anchored in both the interstitial matrix and basement mem-
brane and could therefore potentially be used to describe 
disease activity in PsA.
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N-3 PUFA, especially long-chain n-3 PUFA like eicosap-
entaenoic acid (EPA) and docosahexaenoic acid (DHA), has 
shown bone-protective effects in animal models by inhib-
iting bone resorption and promoting bone formation [35]. 
Several studies in humans have also been done to assess the 
effect of n-3 PUFA supplementation on bone health, most 
of which are done in healthy individuals, some in patients 
with RA and very few in patients with PsA. Some stud-
ies have reported modulation of bone biomarkers after n-3 
PUFA intervention [34, 36, 37] while others have reported 
no effect [38, 39].
Anti-inflammatory and pro-resolving effects of n-3 
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cipate
Fig. 1  Flowchart of the trial
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The underlying mechanisms responsible for n-3 PUFA’s 
biological effects are mediated by the production of pro-
resolving mediators, which have been proposed to modulate 
and likely resolve inflammatory responses [40]. Therefore, 
various studies have been carried out to explore therapeu-
tic potential of n-3 PUFA supplementation in inflammatory 
diseases including inflammatory arthritides [41]. A number 
of studies have been carried out in patients with RA and 
other inflammatory diseases that have reported an inverse 
correlation between n-3 PUFA use and CRP and erythrocyte 
sedimentation rate [42–44]. In addition to reduced inflam-
mation, n-3 PUFA treatment has also showed a reduced joint 
pain and NSAID use in patients with RA, and a reduction in 
use of NSAIDs and paracetamol in patients with PsA [29]. 
Nevertheless, only a few small studies have examined the 
Table 2  Demographics 
SD standard deviation, BMI body mass index, SJC swollen joint count, TJC tender joint count, ASDAS the 
ankylosing spondylitis disease activity score, BASDAI bath ankylosing spondylitis disease activity index, 
BASMI bath ankylosing spondylitis meterology index, DAS-28 disease activity score-28 joints, LEI Leeds 
enthesitis index, PASI Psoriasis area and severity index, SPARCC spondyloarthritis research consortium of 
canada, CRP C-reactive protein, VAS visual analounge scale, NSAID non steroidal anti-inflammatory drug, 








Mean age (SD) 39.6 (11.8) 50.7 (11.5) 53.0 (11.4)  < 0.001
Gender, female (%) 22 (37%) 43 (60.6) 40 (55.6) 0.038
PsA duration N/A 13.4 (8.9) 13.4 (10.0) 0.983
BMI (kg/m2) N/A 28.0 (5.0) 28.6 (5.8) 0.529
Smoking, n (%)
 Non-smoker N/A 41 (57.7) 36 (50.0) 0.164
 Former smoker 14 (19.7) 27 (37.5)
 Current smoker 16 (22.5) 9 (12.5)
SJC N/A 0.8 (2.0) 0.6 (1.9) 0.420
TJC N/A 4.0 (5.9) 5.1 (9.6) 0.424
ASDAS N/A 2.3 (1.1) 2.0 (0.9) 0.038
BASDAI N/A 38.1 (26.3) 32.6 (24.1) 0.199
BASMI N/A 1.1 (4.0) 1.5 (7.3) 0.669
DAS-28 N/A 2.7 (0.9) 2.5 (0.9) 0.188
LEI N/A 1.3 (1.6) 1.3 (1.7) 0.802
PASI N/A 2.3 (4.0) 2.2 (3.0) 0.897
SPARCC N/A 2.7 (3.3) 2.5 (3.3) 0.703
CRP (mg/L) N/A 6.1 (7.7) 4.6 (4.2) 0.149
VAS pain N/A 37.0 (24.3) 29.80 (24.0) 0.085
NSAID use n (%) N/A 32 (45.1) 40 (55.6) 0.746
DMARD use n (%) N/A 50 (70.4) 57 (79.2) 0.136
Documented coronary heart dis-
ease, n (%)
N/A 4 (5.6) 4 (5.6) 1.000
Hypertension, n (%) N/A 20 (28.2) 21 (29.2) 0.813
Hypercholesterolemia, n (%) N/A 11 (15.5) 18 (25.0) 0.147
Total cholesterol, (mmol/l) N/A 4.8 (0.8) 5.0 (1.0) 0.196
Systolic BP, (mmHg) N/A 134.3 (19.2) 137.8 (18.0) 0.275
Diastolic BP, (mmHg) N/A 82.0 (12.3) 82.7 (10.9) 0.699
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effect of n-3 PUFA on clinical outcomes and inflammation 
in patients with PsA with diverging results [45–47].
In general, several studies have indicated a disturbance in 
lipids in PsA patients, by an increased serum concentration 
of triglycerides, cholesterol, LDH and HDL [48, 49]. Satu-
rated fatty acids (myristic acid, palmitic acid, stearic acid, 
arachidic acid, behenic acid, lognoceric acid) are believed 
to have pro-inflammatory effects, while MUFA (palmutoleic 
acid, oleic acid, nervonic acid) and PUFA have shown anti-
inflammatory effects [50]. In addition, the compositions of 
fatty acids, are less important that the overall fatty acid com-
position [51]. Due to lack of research within the composi-
tion of fatty acids in PsA, only speculations on how tissue 
biomarkers will be modulated dependent on the fatty acid 
supplement.
In this study, we were unable to demonstrate any changes 
in biomarkers of bone and tissue turnover after interven-
tion. Only a significant change was found with an increase 
in PRO-C3 from baseline to 24 weeks, however no relevant 
clinical finding. The primary outcomes of the clinical trial 
were not reached and indicated no difference in placebo 
vs. n-3 PUFA supplement which may describe the lack of 
changes in the biomarkers [29]. Supplementation with n-3 
PUFA for 24 weeks might be too short a period to observe 
changes and modulation in these biomarkers. Furthermore, 
patients in this study had a low mean disease activity score 
of 2.6 (SD = 0.9) at baseline and 75% of the patients received 
disease-modifying antirheumatic drugs. Thus, we investi-
gated a patient group in remission and results may not apply 
to patients with a more severely disease activity or patients 
not receiving DMARDs.
Limitations and strengths
The present study had some limitations. First, olive oil was 
used as placebo and while there are reports on the use of 
olive oil for this purpose in studies investigating the effects 
of n-3 PUFA [23, 52], it may itself have anti-inflammatory 
effects owing to its numerous phenol constituents [53]. 
These effects of olive oil might explain the lack of a sig-
nificant difference in inflammatory biomarkers between the 
groups. Second, patients with all disease activity scores were 
included in the study and they had a low disease activity at 
baseline (low mean swollen and tender joint count, enthesitis 
Table 3  Correlations between biomarkers and clinical scores
Ns = non significant
Biomarker ASDAS-CRP DAS-28-CRP TJC PASI SJC LEI SPARCC HAQ BASDAI VAS pain
OC Ns Ns Ns Ns r = − 0.234
p = 0.005
Ns Ns Ns Ns Ns
CTX-I Ns Ns Ns r = − 0.247
p = 0.003
Ns Ns Ns Ns Ns
PRO-C1 Ns Ns Ns Ns r = − 0.236
p = 0.005
Ns Ns Ns Ns Ns
PRO-C3 Ns Ns r = − 0.267
p = 0.01
Ns Ns Ns Ns Ns Ns Ns
PRO-C4 Ns Ns Ns Ns Ns Ns Ns Ns Ns Ns
C1M Ns Ns Ns Ns Ns Ns Ns Ns Ns Ns
C3M Ns Ns Ns Ns Ns Ns r = 0.171
p = 0.042
Ns Ns Ns
C4M Ns Ns Ns Ns Ns Ns Ns Ns Ns Ns
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Fig. 2  Levels of collagen formation and degradation biomarkers in 
serum from healthy controls (n = 57) and patients with PsA (n = 142). 
a. Serum levels of formation of collagen type I (PRO-C1), b. Serum 
levels of degradation of collagen type I (C1M), c. Serum levels of 
formation of collagen type III (PRO-C3), d. Serum levels of degra-
dation of collagen type III, e. Serum levels of formation of collagen 
type VI (PRO-C4), b. Serum levels of degradation of collagen type 
IV (C4M). Statistical differences between the healthy controls and 
PsA patients were calculated using an unpaired t test for PRO-C3, 
and LOG10 transformed PRO-C1, C1M, C3M, PRO-C4 and C4M. 
Significance threshold was set at p < 0.05 and data is presented as 
Tukey boxplots. Significance levels: ****p < 0.0001
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score and PASI) owing to DMARD use in about 75% and 
NSAID use in 50% of the patients. Third, the effect of n-3 
PUFA on clinical outcomes and thereby biomarkers is likely 
to be small in comparison to DMARDs, thus requiring a 
larger sample size. Lastly, blood samples were not collected 
in fasting state for this study, which could have influenced 
the results, especially CTX-I.
The main strength of the study is the double-blind, rand-
omized, and prospective design comparing subjects which 
are biologic naïve. Furthermore, the compliance rate was 
good and only few patients were lost to follow-up.
Conclusion
Patients with PsA showed an imbalanced ECM turnover 
compared to healthy individuals. No major differences were 
found for the biomarkers when the patients were treated with 
n-3 PUFA for 24 weeks. This indicates that tissue remodel-
ling is occurring in the PsA patients compared to healthy 
individuals, but the n-3 PUFA treatment for 24 weeks does 
not have an effect on ECM turnover. However, further long-
term studies are required to evaluate the potential effect of 
n-3 PUFA on PsA.
Fig. 3  Levels of bone formation and degradation biomarkers in serum 
from healthy controls (n = 6) and patients with PsA (n = 142). a. 
Serum levels of bone formation measured by osteocalcin (OC) and 
b. Serum levels of bone degradation measured by CTX-I. Statistical 
differences between the healthy controls and PsA patients were calcu-
lated using an unpaired t test for OC, and LOG10 transformed CTX-I. 
Data is presented as Tukey boxplots
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Fig. 4  Biomarker levels in 
placebo (n = 57) and n-3 PUFA 
(n = 142) treated patients at 
baseline and 24 weeks. a Serum 
levels of the bone formation 
biomarker osteocalcin (OC), 
b Serum levels of the bone 
degradation biomarker CTX-I, 
c Serum levels of the collagen 
type I biomarker, PRO-C1, d 
Serum levels of the collagen 
type III formation biomarker, 
PRO-C3, e Serum levels of 
the collagen type IV formation 
biomarker, PRO-C4, f Serum 
levels of the collagen type I 
degradation biomarker, C1M, 
g Serum levels of the collagen 
type III degradation biomarker 
C3M, and h Serum levels of the 
collagen type IV degradation 
biomarker, C4M. Statistical 
differences between the baseline 
and 24 weeks of follow-up 
were calculated using a paired 
t test for OC and PRO-C3, and 
LOG10 transformed CTX-I 
PRO-C1, C1M, C3M, PRO-C4 
and C4M. Significance thresh-
old was set at p < 0.05 and data 
is presented as Tukey boxplots. 
Significance levels: **p < 0.01
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